Cytogen Corporation (Nasdaq: CYTO)

https://www.cytogen.com

Cytogen is a specialty pharmaceutical company dedicated to advancing the treatment and care of patients by building, developing, and commercializing a portfolio of oncology products. The Company's specialized sales force currently markets three therapeutic products and one diagnostic product to the U.S. oncology market. CAPHOSOL(R) is an advanced electrolyte solution for the treatment of oral mucositis and dry mouth that is approved in the U.S. as a prescription medical device. QUADRAMET(R) (samarium Sm-153 lexidronam injection) is approved for the treatment of pain in patients whose cancer has spread to the bone. PROSTASCINT(R) (capromab pendetide) is a PSMA-targeting monoclonal antibody-based agent to image the extent and spread of prostate cancer and SOLTAMOX(TM) (tamoxifen citrate) is the first liquid hormonal therapy approved in the U.S. for the treatment of breast cancer in adjuvant and metastatic settings. The Company is also developing CYT-500, a third-generation radiolabeled antibody to treat prostate cancer. Cytogen's product-focused strategy centers on attaining sustainable growth through clinical, commercial, and strategic initiatives. *

	Start	1990-07-01 existent
	Group	Jazz Pharmaceuticals (Group)
	Industry	BIOTECH

	Region	Princeton, NJ
	Country	United States (USA)
	Street	650 College Road East, Suite 3100
	City	08540 Princeton, NJ
	Tel	+1-609-750-8200
		Address record changed: 2020-12-02

Basic data	Employees	n. a.
	Currency	USD
	Cash	3,090,000 (2008-03-31)

		* Document for »About Section«:

		Record changed: 2023-07-10